brentuximab vedotin
takeda,seagen
['echelon-1', 'echelon']
updated analysis of echelon-1 at #asco22 showed os benefit to bv-avd arm compared to abvd in untreated advanced stage chl! - median fu 73 mo
- 6 yr os 93.9% vs. 89.%
- hr for os 0.59 (95%ci 0.396-0.879; p=0.009)
- fewer secondary malignancies w bv-avd
Lymphoma MD at University of Michigan, intent on ensuring optimal health care delivery and hiking every national park in the US. 

All opinions my own.